Synkoloid Company Asbestos Exposure: Joint Compound, ARTRA Trust Claims & Compensation

Synkoloid Company manufactured construction and surface-finishing products, including historical asbestos-containing joint compounds. The strongest official evidence now comes from the ARTRA 524(g) Asbestos Trust. Its Trust Distribution Procedures state that ARTRA acquired Synkoloid’s assets in 1975 and assumed post-1962 liabilities, and that Synkoloid distributed asbestos-containing products from 1949 through 1976. Published litigation also documents construction workers who personally used or worked around Synkoloid joint compound.

ARTRA Group filed Chapter 11 in 2002 as asbestos liabilities connected to its former ownership of Synkoloid mounted. ARTRA’s confirmed reorganization created the ARTRA 524(g) Asbestos Trust in 2007 to resolve qualifying present and future asbestos personal-injury claims. The Trust remains active. Its official 2025 notice increased the Payment Percentage from 0.60% to 0.70%, effective April 1, 2025. The current TDP lists a $275,000 Scheduled Value for mesothelioma, but actual payment is subject to the applicable Payment Percentage and all Trust requirements.

🏢 Synkoloid History & ARTRA Bankruptcy

Synkoloid’s asbestos liabilities ultimately became part of ARTRA’s Chapter 11 reorganization. SEC filings confirm that the ARTRA plan created an asbestos trust, transferred assets to it, and imposed a channeling injunction covering qualifying asbestos claims. The plan became effective April 2, 2007.

Synkoloid / ARTRA Facts

Topic	Confirmed information
Company	The Synkoloid Company.
Historical asbestos period in TDP	1949 through 1976 for Synkoloid distribution of asbestos-containing products.
ARTRA acquisition	1975.
Liabilities assumed	TDP states ARTRA assumed post-1962 Synkoloid liabilities.
ARTRA Chapter 11	June 3, 2002.
Plan confirmation	January 25, 2007; District Court affirmed February 28, 2007.
Plan effective date	April 2, 2007.
Trust	ARTRA 524(g) Asbestos Trust.

Bankruptcy / Trust Timeline

Period	Development
1949–1976	TDP identifies this period for Synkoloid distribution of asbestos-containing products.
1975	ARTRA acquired Synkoloid assets and assumed specified liabilities.
1981	ARTRA later sold Synkoloid; asbestos liabilities remained central to later proceedings.
June 3, 2002	ARTRA filed Chapter 11.
January 2007	Bankruptcy Court confirmed ARTRA reorganization plan.
April 2, 2007	Plan effective; asbestos trust framework implemented.
April 1, 2025	Trust Payment Percentage increased from 0.60% to 0.70%.

See Construction Materials Companies & Asbestos Exposure.

🧱 Synkoloid Asbestos Joint Compounds

The ARTRA Trust publishes an official list of asbestos-containing ARTRA/Synkoloid products. The TDP itself specifically discusses joint-compound exposure and defines a coworker as someone able to provide sworn testimony that a claimant worked with or around joint-compound products while ARTRA asbestos-containing products were present.

Historical Synkoloid Product Evidence

Product / category	Evidence-based treatment
Triple Duty Joint Compound	Historically identified Synkoloid joint compound in asbestos litigation and Trust materials.
Synko-Topping	Historically identified Synkoloid finishing/joint compound.
Joint compounds generally	Trust TDP expressly addresses work with or around joint-compound products.
Other listed Synkoloid/ARTRA products	Use the Trust’s official asbestos-containing product list for claim-specific identification.
Modern products using similar brand names	Do not assume asbestos content from historical formulations.

Product Accuracy Rules

Statement	Accurate treatment
Synkoloid distributed asbestos-containing products	Confirmed by official ARTRA TDP.
Historical period 1949–1976	Explicitly stated in the TDP.
Every Synkoloid product contained asbestos	Not established.
Every product sold after 1976 contained asbestos	Not supported.
Brand name alone proves exposure	No.
Trust’s official product list should guide identification	Yes.

👷 Workers, Trades & Jobsites

Synkoloid joint compounds were associated with drywall and surface-finishing work. Published California litigation documents a construction worker who worked around or personally used joint compound from Synkoloid and other manufacturers. Trust exposure rules focus on meaningful and credible exposure to an ARTRA or predecessor asbestos-containing product before January 1, 1983.

Workers & Trades to Investigate

Worker / trade	Potential historical activity
Drywall finishers / tapers	Mixing, applying and sanding joint compound.
Painters	Surface preparation and sanding near joint compound.
Carpenters / remodelers	Drywall installation and repair.
Cement masons / nearby trades	Working in areas where joint compound was mixed or sanded.
Construction laborers	Mixing, cleanup and debris handling.
Maintenance workers	Wall and ceiling repair.
DIY home renovators	Historical drywall finishing and remodeling.

Jobsite Evidence

Evidence	Why useful
Approved site evidence	TDP permits presumptive exposure evidence at known sites when requirements are met.
Employment records	Establish employer, trade and dates.
Invoices / purchase records	May identify Synkoloid products.
Product bags / photographs	Can strengthen product identification.
Coworker affidavit	Expressly contemplated by TDP.
Construction records	May establish work location and relevant period.

Need help now? Call 800.291.0963
Live chat is available 24/7, 365 days a year.
Submit Your Case

🌫️ How Synkoloid Asbestos Exposure Occurred

Drywall joint compound can generate dust when dry material is mixed and when hardened compound is sanded. In a Synkoloid claim, however, the key legal and Trust issue is not merely whether drywall dust existed—it is whether credible evidence connects the claimant to a qualifying asbestos-containing Synkoloid/ARTRA product.

Potential Exposure Activities

Activity	Potential pathway
Opening dry compound	Dust during handling of powdered material.
Mixing	Airborne dust while preparing compound.
Application	Handling qualifying historical material.
Sanding	Dust generated from dried compound.
Cleanup	Re-suspension of settled dust.
Demolition / renovation	Disturbance of historical wall finishes.

Exposure Questions

Question	Why it matters
Was the product Synkoloid/ARTRA?	Trust legal responsibility must be established.
Did it contain asbestos?	Product-specific evidence matters.
Did exposure occur before Jan. 1, 1983?	Current TDP requires ARTRA Exposure before that date.
What task was performed?	Supports exposure pathway.
Was Significant Occupational Exposure required?	Required for several Disease Levels under Expedited Review.
Can records or witnesses corroborate exposure?	TDP permits affidavits and contemporaneous records.

⚖️ ARTRA Asbestos Trust & Synkoloid Claims

The ARTRA 524(g) Asbestos Trust is the primary trust mechanism for qualifying asbestos claims arising from products for which ARTRA and its predecessors have legal responsibility, including qualifying Synkoloid exposure. The Trust’s official February 2025 notice states that its Payment Percentage increased from 0.60% to 0.70%, effective April 1, 2025, and remains 0.70% until further adjustment.

Current Trust Facts

Trust fact	Confirmed information
Trust	ARTRA 524(g) Asbestos Trust.
Created through	ARTRA Chapter 11 reorganization.
Plan effective	April 2, 2007.
Current Payment Percentage	0.70%, effective April 1, 2025.
Immediately prior percentage	0.60%.
Claim filing fee	$50 for claims filed on or after April 1, 2025.
Exposure cutoff	Meaningful and credible ARTRA Exposure must have occurred before January 1, 1983.
Individual Review	TDP states it is eliminated except for Foreign Claims.

Official Scheduled Values

Disease Level	Scheduled Value
Level VI — Mesothelioma	$275,000.
Level V — Lung Cancer	$40,000.
Level IV — Other Cancer	$10,000.
Level III — Severe Asbestosis	$40,000.
Level II — Asbestosis/Pleural Disease	$6,000.
Level I — Other Asbestos Disease	Eliminated as of September 13, 2011.

0.70% Mathematical Examples

Scheduled Value	Illustrative payment at 0.70%
$275,000 mesothelioma	$1,925.
$40,000 lung cancer	$280.
$10,000 other cancer	$70.
$40,000 severe asbestosis	$280.
$6,000 asbestosis/pleural disease	$42.

These are mathematical illustrations, not guaranteed payments. The TDP subjects liquidated claims to the applicable Payment Percentage and other Trust provisions, including FIFO payment, Maximum Annual Payment and Claims Payment Ratio limitations.

📊 Documented Synkoloid Asbestos Cases

Court and SEC records independently document Synkoloid asbestos liabilities. A federal district court reviewing the Pace dispute stated that a Texas jury entered a $2.025 million judgment against Synkoloid and that ARTRA was the entity responsible for Synkoloid asbestos liabilities. The case later involved a settlement agreement; an individual historical verdict should not be used as a prediction of current Trust compensation.

Selected Records

Record	Significance
Pace federal decision, N.D. Ill. (2010)	Recites $2.025 million Texas judgment against Synkoloid and ARTRA responsibility for Synkoloid asbestos liabilities; later settlement issues followed.
Silvestro v. Kaiser Gypsum, Cal. Ct. App. (2009)	Documents worker’s use/work around Synkoloid joint compound among multiple manufacturers.
ARTRA Trust v. Transport Insurance, N.D. Ill. (2011)	States ARTRA filed bankruptcy due to mounting liabilities from ownership of Synkoloid, which manufactured/sold/distributed asbestos-containing products.
SEC 2007 filing	Confirms ARTRA plan, trust creation, channeling injunction and April 2, 2007 effective date.
Official 2025 Trust notice	Confirms 0.70% Payment Percentage effective April 1, 2025.

Evidence Limits

Finding	Correct interpretation
Synkoloid asbestos liabilities	Strongly documented.
Historical asbestos-containing products	Confirmed.
Every Synkoloid product asbestos-containing	Not established.
Pace verdict predicts current claim value	No.
0.70% guarantees payment	No.
Use of joint compound alone proves ARTRA exposure	No; TDP evidence requirements apply.

📋 Claim Evidence & Trust Requirements

The TDP requires meaningful and credible ARTRA Exposure before January 1, 1983. Evidence may include claimant, coworker or family-member affidavits, invoices, construction records and other contemporaneous documents. Several disease levels also require Significant Occupational Exposure.

Evidence That May Help

Medical and pathology documentation.
Employment, union and Social Security records.
Synkoloid product bags, labels, photographs or receipts.
Invoices and construction records.
Claimant or coworker affidavits.
Evidence of mixing, sanding or other dust-producing work.
Approved-site evidence where applicable.
Current Trust claim form and required filing fee.

Claim Checklist

Step	Question
1	Is a compensable Disease Level documented?
2	Did qualifying ARTRA/Synkoloid exposure occur before Jan. 1, 1983?
3	Can an asbestos-containing product be identified?
4	Are site, trade and dates documented?
5	Is Significant Occupational Exposure required and established?
6	Are affidavits or contemporaneous records available?
7	Has the current 0.70% Payment Percentage been verified?
8	Has the $50 filing-fee procedure been followed if applicable?

Numbers We Do Not Invent

Item	Treatment
Current Trust assets	Not stated without a current official financial report.
Average Synkoloid payout	Not inferred from verdicts or Scheduled Values.
Current total claims paid	Not stated without official current reporting.
Guaranteed mesothelioma payment	None.
Future Payment Percentage	Can change under TDP.
Guaranteed compensation	None.

Compensation is not guaranteed.

❓ Frequently Asked Questions

Did Synkoloid manufacture asbestos-containing products?

Yes. The official ARTRA Trust TDP states that Synkoloid distributed asbestos-containing products from 1949 through 1976, and litigation documents Synkoloid joint-compound exposure.

What Synkoloid products are associated with asbestos exposure?

Historical joint compounds, including Triple Duty Joint Compound and Synko-Topping, are associated with Synkoloid asbestos claims. Claimants should use the Trust’s official asbestos-containing product list for product-specific proof.

When did ARTRA acquire Synkoloid?

The ARTRA Trust TDP states that ARTRA acquired Synkoloid’s assets in 1975 and assumed post-1962 liabilities.

Does Synkoloid have an asbestos trust?

Qualifying Synkoloid-related liabilities are handled through the ARTRA 524(g) Asbestos Trust created through ARTRA’s Chapter 11 reorganization.

What is the current ARTRA Trust Payment Percentage?

The Trust’s official notice increased the Payment Percentage from 0.60% to 0.70%, effective April 1, 2025, and states it remains at 0.70% until further adjusted.

What is the Scheduled Value for mesothelioma?

The Second Amended TDP lists $275,000 for Level VI mesothelioma. At 0.70%, $275,000 × 0.007 equals $1,925 as a mathematical illustration, not a guaranteed payment.

What exposure date does the Trust require?

The TDP requires meaningful and credible exposure before January 1, 1983 to an asbestos-containing product for which ARTRA or its predecessors have legal responsibility.

Is there a filing fee?

Yes. The Trust’s official notice requires a $50 filing fee for each asbestos claim filed on or after April 1, 2025, subject to the Trust’s filing-fee procedures.

🧾 Synkoloid Company Asbestos Summary

Detail	Confirmed / carefully qualified information
Historical asbestos company	Synkoloid Company.
TDP asbestos-product period	1949–1976.
ARTRA acquisition	1975.
ARTRA Chapter 11	June 3, 2002.
Trust	ARTRA 524(g) Asbestos Trust.
Plan effective	April 2, 2007.
Current Payment Percentage	0.70%, effective April 1, 2025.
Mesothelioma Scheduled Value	$275,000.
Lung Cancer Scheduled Value	$40,000.
Filing fee	$50 for claims filed on/after April 1, 2025.
Guaranteed compensation	No.

📚 Confirmed Primary & Court Sources

Submit Your Case

Call 800.291.0963
Live chat is available 24/7, 365 days a year.
Submit Your Case

Working with or around a Synkoloid product does not automatically establish a compensable asbestos claim. Product identity, asbestos content, exposure dates, work activity, medical evidence and current ARTRA Trust Distribution Procedures must be evaluated individually. Compensation is not guaranteed.

⚕️ Legal & Medical Information Disclaimer
This page provides general educational information and is not legal or medical advice. Consult qualified healthcare and legal professionals for individual guidance.